This poster examines mortality from hematologic malignancies in U.S. adults who also have alcoholic liver disease or cirrhosis — a combination that is increasingly common yet poorly characterized nationally, since liver disease may worsen cancer outcomes through immune dysfunction and restricted treatment options. Using the CDC WONDER database, we retrospectively analyzed adults aged ≥25 years carrying both diagnoses (ICD-10 C81–C96 and K70, K73, K74) between 1999 and 2024, calculating age-adjusted mortality rates (AAMRs) per 1,000,000 and annual percentage changes, stratified by sex, race/ethnicity, U.S. region, and age group (25–34 to ≥85 years) using Joinpoint regression. We identified 14,660 deaths, with an average AAMR of 2.4 that climbed steadily from 1.9 in 1999 to 3.6 in 2024 (APC 2.9). Mortality was substantially higher in males than females (3.5 vs 1.4, AAPC 3.3 vs 2.9), highest among non-Hispanic American Indian individuals (4.8) and lowest among non-Hispanic Asian individuals (1.3), and highest in the West (2.7) compared with the Northeast (2.0). Together these findings demonstrate a consistently rising burden marked by clear demographic and geographic disparities, supporting closer attention to coexisting liver disease when evaluating outcomes in patients with hematologic cancers.